Edition:
India

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

76.42USD
18 Jul 2018
Change (% chg)

$-1.61 (-2.06%)
Prev Close
$78.03
Open
$77.93
Day's High
$78.33
Day's Low
$75.74
Volume
362,964
Avg. Vol
318,264
52-wk High
$95.82
52-wk Low
$63.69

Chart for

About

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $12,381.50
Shares Outstanding(Mil.): 142.61
Dividend: 0.16
Yield (%): 0.74

Financials

  PRGO.N Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -20.55 -- --
ROI: -22.33 15.07 14.61
ROE: -38.96 16.60 16.34

AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge

A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

30 Jun 2018

BRIEF-Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg

* ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES

16 May 2018

BRIEF-Perrigo Says Terminated Existing Credit Agreements

* PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT

10 Mar 2018

BRIEF-Perrigo - John Hendrickson's 2017 Total Compensation $8.3 Million Versus $5.8 Million In 2016

* PERRIGO COMPANY PLC CEO JOHN HENDRICKSON'S 2017 TOTAL COMPENSATION $8.3 MILLION VERSUS $5.8 MILLION IN 2016 - SEC FILING

10 Mar 2018

BRIEF-Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5

* PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING Source text: (http://bit.ly/2Fpn04Z) Further company coverage:

08 Mar 2018

BRIEF-Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS

07 Mar 2018

BRIEF-Perrigo Company Q4 GAAP Earnings Per Share $0.52

* REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS

02 Mar 2018

BRIEF-Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results

* REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%

* PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF FINACEA® FOAM, 15%

20 Feb 2018

BRIEF-Perrigo Appoints Ronald Winowiecki As CFO

* PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER

20 Feb 2018

Earnings vs. Estimates